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of mTORC1 in mature adipocytes results
in loss of triglycerides. To examine this
in vivo, raptor was deleted in mature adi-
pocytes, resulting in lean mice with a re-
duction in both adipocyte size and num-
ber. As seen in other lean mouse models,
raptor adipose KO mice are resistant to
diet-induced obesity and exhibit insulin
hypersensitivity with improved glucose
tolerance. The insulin sensitivity is due to
increased insulin signaling in both adipose
tissue and skeletal muscle. As observed in
the mice lacking raptor in skeletal muscle,
elevated insulin signaling through Akt in
adipose tissue appears to be due to loss
of the mTORC1 negative feedback loop
on IRS-1/PI3K/Akt, paralleling previous
findings from muscle and adipose tissue
in whole-body S6K1 knockout mice on
a high-fat diet (Um et al., 2004).
One molecular basis underlying the
leanness of the mice appears to be ele-
vated energy expenditure, which may be
a consequence of increased mitochon-
drial uncoupling from a 25-fold elevated
level of UCP1 mRNA expression in rap-
tor-deleted white adipose tissue (WAT).
In contrast to adipose tissue, decreases
in PGC1a mRNA were observed in the
raptor-deficient muscle, consistent with
a previous study in C2C12 and mouse
embryonic fibroblasts demonstrating
that inhibition of mTORC1 reduces
PGC1a mRNA through regulation of the
YY-1 transcription factor (Cunningham
et al., 2007). Other possible downstream
effectors for mTORC1 in the control of
muscle and adipose metabolism not ex-
plored in these studies are the key lipo-
genic transcription factor Srebp-1 and
the lipodystrophy protein lipin, both of
which have been previously shown to be
regulated by mTORC1 (Porstmann et al.,
2008; Huffman et al., 2002). Another
well-described function for mTORC1 is
in suppressing autophagy, and future
studies will be needed to define any role
for autophagy in the observed pheno-
types reported here, as well as to further
illuminate the precise downstream effec-
tors of mTORC1 mediating control of
metabolism, tissue homeostasis, and dif-
ferentiation in different tissues.
Taken together, these studies define
critical roles for mTORC1 in metabolic
control in adipose tissue as well as mus-
cle homeostasis. Given that rapamycin
analogs are being examined for the treat-
ment of a host of diseases ranging from
cancer to neurological disease to facets
of metabolic syndrome itself, further dis-
section of the roles of mTORC1 and
mTORC2 in different tissues will provide
future insights into the therapeutic prom-
ise this pathway holds.
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Insulin-triggered trafficking of GLUT4 glucose transporter-loaded vesicles and their fusion with the plasma
membrane are mechanical processes involving multiprotein complexes that coordinate and facilitate vesicle
movement. Now, Yip et al. (2008) link myosin-1c to insulin signaling by demonstrating direct CaMKII-driven
phosphorylation of this critical motor protein.
Insulin signaling in its target tissues of
fat and muscle is known to lead to the
exocytosis of vesicles loaded with the
glucose transporter GLUT4 from an intra-
cellular reservoir compartment to the
plasma membrane. Now, the challenge
for researchers is to link early signaling
to the vesicle-trafficking machinery. Early
events in insulin signaling include the344 Cell Metabolism 8, November 5, 2008 ª2008 Elsevier Inc.
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Previewscoupling of insulin-receptor tyrosine-ki-
nase activity to phosphorylation of the in-
sulin-receptor-substrate molecules IRS1
and IRS2. These steps lead to activation
of PDK1 and PDK2 (mTOR/Rictor), which
in turn lead to the phosphorylation of Akt/
PKB at dual sites. Recent studies have
explored the roles of the Akt substrates
TBC1D1 and TBC1D4 as these proteins
are Rab-GAPs and can therefore poten-
tially link signaling to Rab-facilitated vesi-
cle traffic of GLUT4, reviewed in Saka-
moto and Holman (2008). Now, Yip et al.
(2008) have discovered a new cascade
that links insulin signaling to GLUT4 vesi-
cle traffic; they report that insulin action in
fat cells leads to CaM-KinaseII-mediated
phosphorylation of the motor protein
Myo1c.
Myo1c is a class 1 unconventional my-
osin, present in many tissues, which has
been implicated in vesicle translocation.
Like other unconventional myosins, it is
likely to primarily interact with actin
(Bose et al., 2002), but it has been recently
found to occur in complexes with calmod-
ulin and the G protein RalA (Chen et al.,
2007) and with Rictor (Hagan et al., 2008).
Rictor was discovered as an essential
component of the separate mTORC2
complex that leads to Akt phosphoryla-
tion. However, the association of Rictor
with Myo1c potentially links insulin sig-
naling with a regulated Myo1c and actin
interaction (Hagan et al., 2008). Myo1c
has also been found to be associated
with GLUT4 vesicles (Bose et al., 2002).
Some Myo1c has been found to move to
the vicinity of the plasma membrane in re-
sponse to insulin treatment of target cells
(Bose et al., 2002) and has been directly
implicated in the mechanics of fusion of
GLUT4 vesicles with the plasma mem-
brane (Bose et al., 2004).
Importantly, Yip et al. (2008) now find
that phosphorylation of Myo1c is regu-
lated. They first identified Myo1c as an
interacting partner for the phosphopro-
tein regulator 14-3-3. Among the Myo1c
phosphorylation sites that could poten-
tially bind 14-3-3, only serine 701 showed
reduced 14-3-3 interaction when mutated
to alanine. By use of specific inhibitors of
CaMKII, and by knockdown of the major
CaMKII isoform, Yip et al. (2008) demon-
strate that this kinase is directly required
for phosphorylation of Myo1c on Ser701
in adipocytes. To link the CaMKII-medi-
ated phosphorylation site at Myo1cFigure 1. Linking Insulin Signaling to the Mechanical Process of GLUT4 Vesicle Fusion
Yip et al. propose that regulation of GLUT4 vesicle fusion with the plasma membrane is dependent on the
coordinated control of Akt and of CaMKII. Akt activity is stimulated via activation of the tyrosine kinase
activity of the insulin receptor, PI3-kinase activity and then Akt phosphorylation by the serine kinase com-
plexes of PDK1 and mTORC2 (containing Rictor). A major substrate of Akt is the Rab-GAP protein
TBC1D4, which is inactivated by phosphorylation and binding of 14-3-3 to the phosphorylated protein.
The inactivation of Rab-GAP is thought to facilitate (via a Rab protein) either GLUT4 movement into
a zone close to the plasma membrane or to stimulate GLUT4 vesicle docking. Separately, CaMKII is stim-
ulated by insulin-induced PM calcium flux. Yip et al. propose that this leads to activation of Myo1c phos-
phorylation and dissociation of Myo1c from calmodulin. Binding of 14-3-3 to the phosphorylated Myo1c
does not inactivate its ATPase activity. The localizations of Myo1c complexes in close proximity to the
plasmamembrane and the site of GLUT4 vesicle docking are thought to be critical for stimulation of vesicle
fusion. The relationship of Myo1c/CaMKII, Myo1c/calmodulin, Myo1c/14-3-3, Myo1c/rictor, and Myo1c/
actin to the PI3-kinase pathway is yet to be fully resolved.Ser701 to insulin-regulated GLUT4 trans-
location, Yip et al. (2008) carried out a
series of siRNA experiments. Consistent
with a previous report (Bose et al., 2002),
they report that knockdown of Myo1c re-
duced insulin-stimulated GLUT4 translo-
cation; additionally, this effect is reversed
by reintroduction of wild-type Myo1c
but not by Ser701-to-alanine-mutated
Myo1c.
The requirement for Myo1c interaction
with calmodulin has been investigated
by Yip et al. (2008), and these studies
have led them to propose the mechanism
illustrated in Figure 1. Insulin is thought to
stimulate calcium influx in the area just
below the plasma membrane, which
leads to activation of CaMKII, which then
phosphorylates Myo1c. These steps are
proposed to be associated with or lead
to dissociation of calmodulin from
Myo1c. In support of this hypothesis, Yip
et al. (2008) demonstrate that 14-3-3
binding to phosphorylated Ser701 on
Myo1c, and calmodulin interaction with
Myo1c are mutually exclusive. This phos-
phorylation-driven activation of Myo1c is
associated with increased ATPase activ-
ity, but the 14-3-3 interaction at the phos-Cell Metabolism 8,phorylated site does not alter its ATPase
activity. To complete the experimental
support for the proposed activation cas-
cade, Yip et al. (2008) demonstrate that
the ATPase activity of phosphorylated
Myo1c is required for insulin-stimulated
GLUT4 translocation.
The studies by Yip et al. (2008) have
shown that pharmacological inhibition of
PI3-kinase activity with wortmannin leads
to reduced Myo1c phosphorylation and
14-3-3 binding to phosphorylated
Myo1c. However, wortmannin inhibition
of PI3-kinase does not directly lead to
reduction of insulin-activated CaMKII cat-
alytic activity. Instead, Yip et al. (2008)
have suggested the interesting possibility
that PI 3-kinase activity may be required
for juxtaposing Myo1c and CaMKII.
Some of the effects of Myo1c in the
GLUT4 translocation process are PI
3-kinase independent. Bose et al. (2002)
and (2004) found that insulin-activated
Myo1c translocation to the plasma mem-
brane was PI3-kinase independent and
that high expression ofMyo1c could over-
come a wortmannin (PI3-kinase inhibition)
-induced block in plasma membrane
fusion of GLUT4 vesicles. The separateNovember 5, 2008 ª2008 Elsevier Inc. 345
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actions of Myo1c may perhaps be medi-
ated by distinct Myo1c complexes. It will
be important in future to further resolve
whether PI 3-kinase-dependent or PI 3-ki-
nase-independent actions of Myo1c are
essential to insulin action on GLUT4
translocation, particularly at the GLUT4
vesicle membrane fusion step.
As Yip et al. (2008) suggest, the rela-
tionship of the newly discovered CaMKII
and Myo1c insulin-activated cascade to
the more established activation of
GLUT4 translocation via an Akt cascade
is not fully resolved. A recent report indi-
cates that, in the absence of insulin, Akt
activation alone (using a rapid, chemically
activated form of Akt, the rapalog system)
is sufficient to mimic the effects of insulin
on GLUT4 translocation (Ng et al., 2008).
The full activation of GLUT4 translocation
that results from use of this approach (Ng
et al., 2008) suggests that activation of the
Myo1c cascade must in some way be
associated with the activation of Akt
cascade, as the insulin signaling link to
Myo1c is absent. However, data from
Yip et al. (2008) indicates that activation
of Akt is not directly required for phos-
phorylation of Myo1c at Ser701. Estab-
lishing an alternative means by which
Akt and Myo1c phosphorylation and acti-346 Cell Metabolism 8, November 5, 2008 ªvation are mutually dependent will require
further investigation.
GLUT4 vesicle fusion is now known to
be an important regulated step in the exo-
cytosis pathway (Bose et al., 2004; Lizu-
nov et al., 2005; Koumanov et al., 2005;
Bai et al., 2007). The Yip et al. (2008) study
adds important new data that strengthen
the idea that the mechanical properties
of the Myo1c motor are essential for the
terminal events in GLUT4 vesicle exocy-
tosis. This also appears to be the case
for exocytosis of other channel proteins
(for example, ADH-regulated translocation
of sodium channels [Wagner et al., 2005]).
The Yip et al. (2008) study strengthens the
notion that control of exocytosis may oc-
cur in a specialized fusion zone that oc-
curs, or is generated in response to insulin,
just underneath theplasmamembrane.Al-
thoughCaMKII is activated through insulin
action in muscle, Yip et al. (2008) were not
able to detect Myo1c phosphorylation in
this tissue. An alternative isoform of
Myo1c is therefore likely to be present.
Identifying this motor protein and its
mode of regulation will be important in
the future. Collectively, further studies on
the insulin-regulated motor proteins in fat
and muscle may lead to identification of
novel drug targets for the prevention of in-
sulin resistance and type 2 diabetes.2008 Elsevier Inc.REFERENCES
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